This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
CENTENNIAL, Colo., July 19, 2018 (GLOBE NEWSWIRE) -- A U.S. Senate Committee chose to highlight NioCorp Developments Ltd.’s (“NioCorp” or the "Company”) (TSX:NB) (OTCQX:NIOBF) (FSE:BR3) Elk Creek Critical Minerals Project (the “Project”) because of the uniqueness of the critical minerals it plans to make and because of the Project’s success in reducing its expected environmental impacts.
CENTENNIAL, Colo., July 11, 2018 (GLOBE NEWSWIRE) -- NioCorp Developments Ltd. (“NioCorp” or the "Company”) (TSX:NB) (OTCQX:NIOBF) (FSE:BR3) is pleased to announce that it has agreed to testify on Tuesday, July 17, 2018 before the U.S. Senate Committee on Energy and Natural Resources (the “Committee”) on its Elk Creek, Nebraska Critical Minerals Mine (the “Project”) and on the economic and national security implications of the three superalloy metals it plans to produce.
HD NIOBF NB
CENTENNIAL, Colo., June 28, 2018 (GLOBE NEWSWIRE) -- NioCorp Developments Ltd. (“NioCorp” or the "Company”) (TSX:NB) (OTCQX:NIOBF) (FSE:BR3) is pleased to announce that it has completed and signed a definitive convertible security funding agreement (the "Agreement") with an entity managed by The Lind Partners, a New York based asset management firm (together, “Lind”). A total of US$1.0 million will be funded pursuant to the issuance of a convertible security (the “Convertible Security”), which is expected to occur on or around July 9, 2018.
CENTENNIAL, Colo., June 28, 2018 (GLOBE NEWSWIRE) -- NioCorp Developments Ltd. (“NioCorp” or the "Company”) (TSX:NB) (OTCQX:NIOBF) (FSE:BR3) is pleased to provide an update on the progress of the detailed engineering study being conducted by the Nordmin Group of Companies (“Nordmin”) on NioCorp’s proposed Elk Creek Nebraska, Critical Minerals Mine (the “Project”). The work has determined that incorporating industry-standard ground freezing technology during shaft sinking, coupled with the reduction in underground hydrogeology pumping requirements, may help NioCorp shorten its time to market for the Niobium, Scandium, and Titanium superalloy metals it plans to produce.
In a live webcast, Company also said it expects to see gross margins expand by 10% as a result of new production equipment now being installed in both operating divisions
NIOBF IB IAALF NB
CENTENNIAL, Colo., May 17, 2018 (GLOBE NEWSWIRE) -- The Trump Administration will officially designate as “Critical Minerals” the entire planned product suite of superalloy metals that NioCorp Developments Ltd. (“NioCorp” or the "Company”) (TSX:NB) (OTCQX:NIOBF) (FSE:BR3) proposes to mine and process at its Elk Creek, Nebraska Superalloy Materials project.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to TSX:NB / Niocorp Developments Ltd on message board site Silicon Investor.
|NNBM - SI Branch||CNBC -- critique.|
|Basketball Junkie Forum (NBA)||Binance / BNB|
|GTI.C - Glenbriar Technologies||Canbiola|
|GNBT Generex||Greenblattu0027s Little Book That Beats The Market|
|Neurocrine Biosciences (NBIX)||Nabors Industries(NBR)|